Observational studyJournal of bone and mineral metabolism2020

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.

Hideomi Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.